Breaking News Instant updates and real-time market news.

ARRY

Array BioPharma

$15.06

-0.07 (-0.46%)

08:08
08/07/18
08/07
08:08
08/07/18
08:08

Array BioPharma receives FDA Breakthrough Therapy Designation for BRAFTOVI

Array BioPharma announced it has received Breakthrough Therapy Designation from the U.S. FDA for encorafenib (BRAFTOVI), in combination with binimetinib (MEKTOVI) and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer as detected by an FDA-approved test, after failure of one to two prior lines of therapy for metastatic disease. BRAFV600E-mutant mCRC patients have a mortality risk more than double that of mCRC patients without the mutation, and currently there are no therapies specifically approved for this high unmet need population.

ARRY Array BioPharma
$15.06

-0.07 (-0.46%)

06/20/18
CANT
06/20/18
NO CHANGE
Target $24
CANT
Overweight
Array BioPharma shares could have more room to advance, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein believes Array BioPharma's combination of binimetinib/encorafenib has the "potential to be best-in-class and take a market-leader position." The FDA action date is June 30. Further, the analyst sees opportunity in BRAF+ CRC based on the safety lead-in portion of the Beacon study, which she believes could expand the potential market, with updated results to be presented on June 23. Goldstein thinks Array shares "could have further room to advance" and keeps an Overweight rating on the name with a $24 price target.
06/25/18
PIPR
06/25/18
NO CHANGE
Target $21
PIPR
Overweight
Piper backs Overweight on Array BioPharma after 'impressive' BEACON update
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $21 price target on Array BioPharma after the company reported an "impressive" one-year overall survival rate of 62% from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer. In a research note to investors, Tenthoff also said he is confident in the approval of Braftovi + Mektovi in BRAF-mutant melanoma by the June 30 PDUFA date.
06/25/18
RHCO
06/25/18
NO CHANGE
Target $25
RHCO
Buy
Array BioPharma price target raised to $25 from $19 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Array BioPharma to $25 after the company's updated data from the lead in portion of the Phase 3 BEACON CRC trial of bini/enco/cetuximab. Lawson notes that Array offered survival data for the first time, and that the 12-month OS was "far better" than with SOC regimens at less than 6 months. The analyst believes the findings are "encouraging", increasing his probability of success and market penetration estimates for BEACON CRC while keeping his Buy rating on Array BioPharma.
06/27/18
PIPR
06/27/18
NO CHANGE
Target $25
PIPR
Overweight
Piper ups Array BioPharma price target to $25 after early BRAF-melanoma approval
Piper Jaffray analyst Edward Tenthoff said he is encouraged by the early approval of Array Biopharma's Braftovi and Mektovi combination in BRAF-mutant melanoma ahead of the June 30 PDUFA date and he believes the label "looks good." Tenthoff, who thinks the improved tolerability and "best in class" efficacy of the combination will support rapid uptake, raised his price target on Array shares to $25 from $21 following the approval announcement and he keeps an Overweight rating on the stock.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$272.86

0.27 (0.10%)

, SPX

S&P 500

$0.00

(0.00%)

10:36
11/13/18
11/13
10:36
11/13/18
10:36
Periodicals
Trump considering replacements for chief of staff, DHS secretary, ABC News says »

President Donald Trump is…

SPY

SPDR S&P 500 ETF Trust

$272.86

0.27 (0.10%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$43.97

-0.66 (-1.48%)

, SWI

SolarWinds

$14.94

0.19 (1.29%)

10:35
11/13/18
11/13
10:35
11/13/18
10:35
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

AERI

Aerie Pharmaceuticals

$43.97

-0.66 (-1.48%)

SWI

SolarWinds

$14.94

0.19 (1.29%)

PHAS

PhaseBio

$5.03

(0.00%)

LOGC

LogicBio Therapeutics

$13.87

(0.00%)

CREE

Cree

$42.80

1.27 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 26

    Nov

  • 14

    Mar

LITE

Lumentum

$40.92

3.415 (9.11%)

, BBY

Best Buy

$67.28

0.14 (0.21%)

10:35
11/13/18
11/13
10:35
11/13/18
10:35
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…

LITE

Lumentum

$40.92

3.415 (9.11%)

BBY

Best Buy

$67.28

0.14 (0.21%)

PRGO

Perrigo

$65.43

-0.11 (-0.17%)

SBRA

Sabra Health Care

$20.84

-0.28 (-1.33%)

INFN

Infinera

$4.40

-0.15 (-3.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VERI

Veritone

$6.78

-0.11 (-1.60%)

, NVDA

Nvidia

$196.71

7.34 (3.88%)

10:35
11/13/18
11/13
10:35
11/13/18
10:35
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…

VERI

Veritone

$6.78

-0.11 (-1.60%)

NVDA

Nvidia

$196.71

7.34 (3.88%)

XLNX

Xilinx

$84.02

1.69 (2.05%)

KOP

Koppers Holdings

$21.08

0.88 (4.36%)

SWN

Southwestern Energy

$6.08

0.28 (4.83%)

SAIL

SailPoint

$25.16

0.86 (3.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 20

    Nov

  • 26

    Nov

  • 26

    Nov

  • 27

    Nov

  • 10

    Dec

  • 09

    Jan

10:35
11/13/18
11/13
10:35
11/13/18
10:35
General news
Treasury Action: yields remained pinned lower »

Treasury Action: yields…

10:35
11/13/18
11/13
10:35
11/13/18
10:35
General news
U.S. Retail Sales Face Upside Risks in October: »

U.S. Retail Sales Face…

CBTX

CBTX

$33.14

(0.00%)

10:33
11/13/18
11/13
10:33
11/13/18
10:33
Conference/Events
CBTX management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

XBI

SPDR S&P BIOTECH

$78.80

1.13 (1.45%)

10:30
11/13/18
11/13
10:30
11/13/18
10:30
Options
Second day of big spreads in SPDR Biotech ETF »

Second day of big spreads…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEP

Korea Electric Power

$12.00

0.06 (0.50%)

10:29
11/13/18
11/13
10:29
11/13/18
10:29
Upgrade
Korea Electric Power rating change  »

Korea Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$109.48

0.44 (0.40%)

, SIG

Signet Jewelers

$56.30

0.96 (1.73%)

10:27
11/13/18
11/13
10:27
11/13/18
10:27
Periodicals
Alrosa said to cut low-end diamond prices by as much as 10%, Bloomberg reports »

Retail jewelers that may…

TIF

Tiffany

$109.48

0.44 (0.40%)

SIG

Signet Jewelers

$56.30

0.96 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

TSLA

Tesla

$337.76

6.61 (2.00%)

10:24
11/13/18
11/13
10:24
11/13/18
10:24
Periodicals
Tesla loses legal executive with regulatory experience, Bloomberg reports »

Phil Rothenberg, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 13

    Dec

SRCL

Stericycle

$47.11

0.07 (0.15%)

10:23
11/13/18
11/13
10:23
11/13/18
10:23
Recommendations
Stericycle analyst commentary  »

Stericycle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$177.04

-2.47 (-1.38%)

10:21
11/13/18
11/13
10:21
11/13/18
10:21
Technical Analysis
Technical Take: Home Depot falls after earnings news »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ROST

Ross Stores

$100.34

-1.42 (-1.40%)

10:20
11/13/18
11/13
10:20
11/13/18
10:20
Options
Earnings hedge in Ross Stores »

Earnings hedge in Ross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

10:20
11/13/18
11/13
10:20
11/13/18
10:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

HD

Home Depot

$177.27

-2.24 (-1.25%)

10:19
11/13/18
11/13
10:19
11/13/18
10:19
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

T

AT&T

$30.85

0.05 (0.16%)

10:19
11/13/18
11/13
10:19
11/13/18
10:19
OnTheFly
Trump Effect: CNN suing White House over Jim Acosta’s revoked press credentials »

CNN has announced via…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$194.00

4.63 (2.44%)

10:18
11/13/18
11/13
10:18
11/13/18
10:18
Technical Analysis
Technical Take: Nvidia bounces off lows »

The shares hit an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 10

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/13/18
11/13
10:17
11/13/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

Amag Pharmaceuticals

$18.04

0.07 (0.39%)

10:16
11/13/18
11/13
10:16
11/13/18
10:16
Recommendations
Amag Pharmaceuticals analyst commentary  »

Piper remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 27

    Nov

  • 23

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/13/18
11/13
10:16
11/13/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

Amag Pharmaceuticals

$18.04

0.07 (0.39%)

10:12
11/13/18
11/13
10:12
11/13/18
10:12
Hot Stocks
FDA asks Amag for additional Vyleesi data, January panel meeting on hold »

Amag Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 27

    Nov

  • 23

    Mar

AAL

American Airlines

$37.72

0.85 (2.31%)

10:10
11/13/18
11/13
10:10
11/13/18
10:10
Options
American Airlines attracts short-term call buying as shares advance »

American Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:02
11/13/18
11/13
10:02
11/13/18
10:02
Conference/Events
Washington Association of Money Managers to hold a meeting »

Tapan Gandhi, Principal…

GEOS

Geospace

$14.58

(0.00%)

10:01
11/13/18
11/13
10:01
11/13/18
10:01
Hot Stocks
Geospace announces acquisition of OptoSeis fiber optic technology »

Geospace Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.